Association between Three Therapeutic Strategies and Clinical Outcomes of 2009 FIGO Stage IB2/IIA2 Cervical Cancer

Objective. The aim of this study was to compare clinical outcomes of three therapeutic strategies in patients with stage IB2/IIA2 cervical cancer. Methods. This is a retrospective cohort study. Patients diagnosed with stage IB2/IIA2 cervical cancer between April 2010 and December 2015 at First Affil...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology 2022-08, Vol.2022, p.1-8
Main Authors: Zhang, Yong, Tang, Xiaobi, Ma, Shanshan, Shen, Meizhu, Jiang, Li, Yuan, Wenchao, Wang, Rensheng, Wu, Fang
Format: Article
Language:English
Subjects:
Adjuvant treatment
Age
Blood clots
Cancer
Cancer patients
Cancer therapies
Care and treatment
Cervical cancer
Chemotherapy
Clinical outcomes
Costs
Development and progression
Drug dosages
Hemoglobin
Histology
Hospitalization
Hospitals
Hysterectomy
Length of stay
Lymphatic system
Magnetic resonance imaging
Medical colleges
Medical prognosis
Medical research
Medicine, Experimental
Metastasis
Patient outcomes
Patients
Radiation therapy
Surgery
Tomography
Tumors
Vagina
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c453t-24bc9b1f9e3f2ac4170c5862d26d10b2b00f7fb2d367d09cff7734342c5538b23
cites cdi_FETCH-LOGICAL-c453t-24bc9b1f9e3f2ac4170c5862d26d10b2b00f7fb2d367d09cff7734342c5538b23
container_end_page 8
container_issue
container_start_page 1
container_title Journal of oncology
container_volume 2022
creator Zhang, Yong
Tang, Xiaobi
Ma, Shanshan
Shen, Meizhu
Jiang, Li
Yuan, Wenchao
Wang, Rensheng
Wu, Fang
description Objective. The aim of this study was to compare clinical outcomes of three therapeutic strategies in patients with stage IB2/IIA2 cervical cancer. Methods. This is a retrospective cohort study. Patients diagnosed with stage IB2/IIA2 cervical cancer between April 2010 and December 2015 at First Affiliated Hospital of Guangxi Medical University were included and classed into three groups. The primary outcomes were overall survival (OS) and progression-free survival (PFS). The secondary outcomes included toxicity, hospitalization costs, clinical value, and length of stay. Results. 206 patients were included: 104 used primary surgical treatment (PST), 53 used neoadjuvant chemotherapy followed by radical surgery (NAC + RS), and 49 used concurrent chemoradiotherapy (CCRT). Fewer patients with NAC + RS had deep cervical stromal invasion than primary surgical treatment (PST) (P=0.024). 70.2% of PST and 77.4% in NAC + RS required postoperative radiotherapy or chemoradiotherapy (P=0.634). Median follow-up was 57 months and the 3-year OS and PFS in PST, NAC + RS, and CCRT group were 87.5%, 84.9%, 85.7% and 85.6%, 79.2%, 85.7% (P=0.856 and P=0.424, respectively). Three therapeutic strategies were not associated with OS and PFS. Hospitalization costs were significantly higher in NAC + RS compared to PST (P
doi_str_mv 10.1155/2022/9497798
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9423945</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A716148328</galeid><sourcerecordid>A716148328</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-24bc9b1f9e3f2ac4170c5862d26d10b2b00f7fb2d367d09cff7734342c5538b23</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhi0EoiVw4wesxAUJQvy19vqCFFa0rFQpB8rZ8nrHiauNHezdVvx7nCbi68BlZjTz6J0ZvQi9JvgDIXW9opjSleJKStU8QZdENHLZ8Bo__aO-QC9yvsNYcKzEc3TBBOaCCXaJ0jrnaL2ZfAxVD9MDQKhudwmgREjmAPPkbfV1SmaCrYdcmTBU7eiDt2asNvNk4750o6soxqq66q43hTZbqLpPdNV1a1q1kO4f6dYEC-kleubMmOHVOS_Qt6vPt-2X5c3mumvXN0vLazYtKe-t6olTwBw1lhOJbd0IOlAxENzTHmMnXU8HJuSAlXVOSsYZp7auWdNTtkAfT7qHud_DYCGUJ0Z9SH5v0g8djdd_T4Lf6W2814pTpsoNC_T2LJDi9xnypPc-WxhHEyDOWVOJFSYCk6agb_5B7-KcQnnvkaqLO5z9prZmBO2Di2WvPYrqtSSC8IbRo9b7E2VTzDmB-3UywfpouT5ars-WF_zdCd_5MJgH_3_6J3c6pt8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2709597743</pqid></control><display><type>article</type><title>Association between Three Therapeutic Strategies and Clinical Outcomes of 2009 FIGO Stage IB2/IIA2 Cervical Cancer</title><source>Publicly Available Content Database</source><source>Wiley Open Access</source><source>PubMed Central</source><creator>Zhang, Yong ; Tang, Xiaobi ; Ma, Shanshan ; Shen, Meizhu ; Jiang, Li ; Yuan, Wenchao ; Wang, Rensheng ; Wu, Fang</creator><contributor>Gundamaraju, Rohit ; Rohit Gundamaraju</contributor><creatorcontrib>Zhang, Yong ; Tang, Xiaobi ; Ma, Shanshan ; Shen, Meizhu ; Jiang, Li ; Yuan, Wenchao ; Wang, Rensheng ; Wu, Fang ; Gundamaraju, Rohit ; Rohit Gundamaraju</creatorcontrib><description>Objective. The aim of this study was to compare clinical outcomes of three therapeutic strategies in patients with stage IB2/IIA2 cervical cancer. Methods. This is a retrospective cohort study. Patients diagnosed with stage IB2/IIA2 cervical cancer between April 2010 and December 2015 at First Affiliated Hospital of Guangxi Medical University were included and classed into three groups. The primary outcomes were overall survival (OS) and progression-free survival (PFS). The secondary outcomes included toxicity, hospitalization costs, clinical value, and length of stay. Results. 206 patients were included: 104 used primary surgical treatment (PST), 53 used neoadjuvant chemotherapy followed by radical surgery (NAC + RS), and 49 used concurrent chemoradiotherapy (CCRT). Fewer patients with NAC + RS had deep cervical stromal invasion than primary surgical treatment (PST) (P=0.024). 70.2% of PST and 77.4% in NAC + RS required postoperative radiotherapy or chemoradiotherapy (P=0.634). Median follow-up was 57 months and the 3-year OS and PFS in PST, NAC + RS, and CCRT group were 87.5%, 84.9%, 85.7% and 85.6%, 79.2%, 85.7% (P=0.856 and P=0.424, respectively). Three therapeutic strategies were not associated with OS and PFS. Hospitalization costs were significantly higher in NAC + RS compared to PST (P&lt;0.001) and CCRT (P&lt;0.001). Length of stay in NAC + RS was longer than PST (P&lt;0.001) and CCRT group (P=0.07). Conclusion. The results of this study tend to suggest that the three therapeutic strategies were equivalent treatment options for patients with 2009 FIGO stage IB2/IIA2 cervical cancer. However, prospective larger studies are needed to confirm this. In addition, we did find that concurrent chemoradiotherapy needed shorter treatment time and less cost.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>DOI: 10.1155/2022/9497798</identifier><identifier>PMID: 36046363</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Adjuvant treatment ; Age ; Blood clots ; Cancer ; Cancer patients ; Cancer therapies ; Care and treatment ; Cervical cancer ; Chemotherapy ; Clinical outcomes ; Costs ; Development and progression ; Drug dosages ; Hemoglobin ; Histology ; Hospitalization ; Hospitals ; Hysterectomy ; Length of stay ; Lymphatic system ; Magnetic resonance imaging ; Medical colleges ; Medical prognosis ; Medical research ; Medicine, Experimental ; Metastasis ; Patient outcomes ; Patients ; Radiation therapy ; Surgery ; Tomography ; Tumors ; Vagina</subject><ispartof>Journal of oncology, 2022-08, Vol.2022, p.1-8</ispartof><rights>Copyright © 2022 Yong Zhang et al.</rights><rights>COPYRIGHT 2022 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2022 Yong Zhang et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022 Yong Zhang et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-24bc9b1f9e3f2ac4170c5862d26d10b2b00f7fb2d367d09cff7734342c5538b23</citedby><cites>FETCH-LOGICAL-c453t-24bc9b1f9e3f2ac4170c5862d26d10b2b00f7fb2d367d09cff7734342c5538b23</cites><orcidid>0000-0002-0768-9344 ; 0000-0002-3246-8666</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2709597743/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2709597743?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids></links><search><contributor>Gundamaraju, Rohit</contributor><contributor>Rohit Gundamaraju</contributor><creatorcontrib>Zhang, Yong</creatorcontrib><creatorcontrib>Tang, Xiaobi</creatorcontrib><creatorcontrib>Ma, Shanshan</creatorcontrib><creatorcontrib>Shen, Meizhu</creatorcontrib><creatorcontrib>Jiang, Li</creatorcontrib><creatorcontrib>Yuan, Wenchao</creatorcontrib><creatorcontrib>Wang, Rensheng</creatorcontrib><creatorcontrib>Wu, Fang</creatorcontrib><title>Association between Three Therapeutic Strategies and Clinical Outcomes of 2009 FIGO Stage IB2/IIA2 Cervical Cancer</title><title>Journal of oncology</title><description>Objective. The aim of this study was to compare clinical outcomes of three therapeutic strategies in patients with stage IB2/IIA2 cervical cancer. Methods. This is a retrospective cohort study. Patients diagnosed with stage IB2/IIA2 cervical cancer between April 2010 and December 2015 at First Affiliated Hospital of Guangxi Medical University were included and classed into three groups. The primary outcomes were overall survival (OS) and progression-free survival (PFS). The secondary outcomes included toxicity, hospitalization costs, clinical value, and length of stay. Results. 206 patients were included: 104 used primary surgical treatment (PST), 53 used neoadjuvant chemotherapy followed by radical surgery (NAC + RS), and 49 used concurrent chemoradiotherapy (CCRT). Fewer patients with NAC + RS had deep cervical stromal invasion than primary surgical treatment (PST) (P=0.024). 70.2% of PST and 77.4% in NAC + RS required postoperative radiotherapy or chemoradiotherapy (P=0.634). Median follow-up was 57 months and the 3-year OS and PFS in PST, NAC + RS, and CCRT group were 87.5%, 84.9%, 85.7% and 85.6%, 79.2%, 85.7% (P=0.856 and P=0.424, respectively). Three therapeutic strategies were not associated with OS and PFS. Hospitalization costs were significantly higher in NAC + RS compared to PST (P&lt;0.001) and CCRT (P&lt;0.001). Length of stay in NAC + RS was longer than PST (P&lt;0.001) and CCRT group (P=0.07). Conclusion. The results of this study tend to suggest that the three therapeutic strategies were equivalent treatment options for patients with 2009 FIGO stage IB2/IIA2 cervical cancer. However, prospective larger studies are needed to confirm this. In addition, we did find that concurrent chemoradiotherapy needed shorter treatment time and less cost.</description><subject>Adjuvant treatment</subject><subject>Age</subject><subject>Blood clots</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cervical cancer</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Costs</subject><subject>Development and progression</subject><subject>Drug dosages</subject><subject>Hemoglobin</subject><subject>Histology</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Hysterectomy</subject><subject>Length of stay</subject><subject>Lymphatic system</subject><subject>Magnetic resonance imaging</subject><subject>Medical colleges</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Metastasis</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>Surgery</subject><subject>Tomography</subject><subject>Tumors</subject><subject>Vagina</subject><issn>1687-8450</issn><issn>1687-8450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kU1vEzEQhi0EoiVw4wesxAUJQvy19vqCFFa0rFQpB8rZ8nrHiauNHezdVvx7nCbi68BlZjTz6J0ZvQi9JvgDIXW9opjSleJKStU8QZdENHLZ8Bo__aO-QC9yvsNYcKzEc3TBBOaCCXaJ0jrnaL2ZfAxVD9MDQKhudwmgREjmAPPkbfV1SmaCrYdcmTBU7eiDt2asNvNk4750o6soxqq66q43hTZbqLpPdNV1a1q1kO4f6dYEC-kleubMmOHVOS_Qt6vPt-2X5c3mumvXN0vLazYtKe-t6olTwBw1lhOJbd0IOlAxENzTHmMnXU8HJuSAlXVOSsYZp7auWdNTtkAfT7qHud_DYCGUJ0Z9SH5v0g8djdd_T4Lf6W2814pTpsoNC_T2LJDi9xnypPc-WxhHEyDOWVOJFSYCk6agb_5B7-KcQnnvkaqLO5z9prZmBO2Di2WvPYrqtSSC8IbRo9b7E2VTzDmB-3UywfpouT5ars-WF_zdCd_5MJgH_3_6J3c6pt8</recordid><startdate>20220822</startdate><enddate>20220822</enddate><creator>Zhang, Yong</creator><creator>Tang, Xiaobi</creator><creator>Ma, Shanshan</creator><creator>Shen, Meizhu</creator><creator>Jiang, Li</creator><creator>Yuan, Wenchao</creator><creator>Wang, Rensheng</creator><creator>Wu, Fang</creator><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0768-9344</orcidid><orcidid>https://orcid.org/0000-0002-3246-8666</orcidid></search><sort><creationdate>20220822</creationdate><title>Association between Three Therapeutic Strategies and Clinical Outcomes of 2009 FIGO Stage IB2/IIA2 Cervical Cancer</title><author>Zhang, Yong ; Tang, Xiaobi ; Ma, Shanshan ; Shen, Meizhu ; Jiang, Li ; Yuan, Wenchao ; Wang, Rensheng ; Wu, Fang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-24bc9b1f9e3f2ac4170c5862d26d10b2b00f7fb2d367d09cff7734342c5538b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adjuvant treatment</topic><topic>Age</topic><topic>Blood clots</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cervical cancer</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Costs</topic><topic>Development and progression</topic><topic>Drug dosages</topic><topic>Hemoglobin</topic><topic>Histology</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Hysterectomy</topic><topic>Length of stay</topic><topic>Lymphatic system</topic><topic>Magnetic resonance imaging</topic><topic>Medical colleges</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Metastasis</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>Surgery</topic><topic>Tomography</topic><topic>Tumors</topic><topic>Vagina</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yong</creatorcontrib><creatorcontrib>Tang, Xiaobi</creatorcontrib><creatorcontrib>Ma, Shanshan</creatorcontrib><creatorcontrib>Shen, Meizhu</creatorcontrib><creatorcontrib>Jiang, Li</creatorcontrib><creatorcontrib>Yuan, Wenchao</creatorcontrib><creatorcontrib>Wang, Rensheng</creatorcontrib><creatorcontrib>Wu, Fang</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yong</au><au>Tang, Xiaobi</au><au>Ma, Shanshan</au><au>Shen, Meizhu</au><au>Jiang, Li</au><au>Yuan, Wenchao</au><au>Wang, Rensheng</au><au>Wu, Fang</au><au>Gundamaraju, Rohit</au><au>Rohit Gundamaraju</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between Three Therapeutic Strategies and Clinical Outcomes of 2009 FIGO Stage IB2/IIA2 Cervical Cancer</atitle><jtitle>Journal of oncology</jtitle><date>2022-08-22</date><risdate>2022</risdate><volume>2022</volume><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><abstract>Objective. The aim of this study was to compare clinical outcomes of three therapeutic strategies in patients with stage IB2/IIA2 cervical cancer. Methods. This is a retrospective cohort study. Patients diagnosed with stage IB2/IIA2 cervical cancer between April 2010 and December 2015 at First Affiliated Hospital of Guangxi Medical University were included and classed into three groups. The primary outcomes were overall survival (OS) and progression-free survival (PFS). The secondary outcomes included toxicity, hospitalization costs, clinical value, and length of stay. Results. 206 patients were included: 104 used primary surgical treatment (PST), 53 used neoadjuvant chemotherapy followed by radical surgery (NAC + RS), and 49 used concurrent chemoradiotherapy (CCRT). Fewer patients with NAC + RS had deep cervical stromal invasion than primary surgical treatment (PST) (P=0.024). 70.2% of PST and 77.4% in NAC + RS required postoperative radiotherapy or chemoradiotherapy (P=0.634). Median follow-up was 57 months and the 3-year OS and PFS in PST, NAC + RS, and CCRT group were 87.5%, 84.9%, 85.7% and 85.6%, 79.2%, 85.7% (P=0.856 and P=0.424, respectively). Three therapeutic strategies were not associated with OS and PFS. Hospitalization costs were significantly higher in NAC + RS compared to PST (P&lt;0.001) and CCRT (P&lt;0.001). Length of stay in NAC + RS was longer than PST (P&lt;0.001) and CCRT group (P=0.07). Conclusion. The results of this study tend to suggest that the three therapeutic strategies were equivalent treatment options for patients with 2009 FIGO stage IB2/IIA2 cervical cancer. However, prospective larger studies are needed to confirm this. In addition, we did find that concurrent chemoradiotherapy needed shorter treatment time and less cost.</abstract><cop>New York</cop><pub>Hindawi</pub><pmid>36046363</pmid><doi>10.1155/2022/9497798</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0768-9344</orcidid><orcidid>https://orcid.org/0000-0002-3246-8666</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1687-8450
ispartof Journal of oncology, 2022-08, Vol.2022, p.1-8
issn 1687-8450
1687-8450
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9423945
source Publicly Available Content Database; Wiley Open Access; PubMed Central
subjects Adjuvant treatment
Age
Blood clots
Cancer
Cancer patients
Cancer therapies
Care and treatment
Cervical cancer
Chemotherapy
Clinical outcomes
Costs
Development and progression
Drug dosages
Hemoglobin
Histology
Hospitalization
Hospitals
Hysterectomy
Length of stay
Lymphatic system
Magnetic resonance imaging
Medical colleges
Medical prognosis
Medical research
Medicine, Experimental
Metastasis
Patient outcomes
Patients
Radiation therapy
Surgery
Tomography
Tumors
Vagina
title Association between Three Therapeutic Strategies and Clinical Outcomes of 2009 FIGO Stage IB2/IIA2 Cervical Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T21%3A15%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20Three%20Therapeutic%20Strategies%20and%20Clinical%20Outcomes%20of%202009%20FIGO%20Stage%20IB2/IIA2%20Cervical%20Cancer&rft.jtitle=Journal%20of%20oncology&rft.au=Zhang,%20Yong&rft.date=2022-08-22&rft.volume=2022&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2022/9497798&rft_dat=%3Cgale_pubme%3EA716148328%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c453t-24bc9b1f9e3f2ac4170c5862d26d10b2b00f7fb2d367d09cff7734342c5538b23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2709597743&rft_id=info:pmid/36046363&rft_galeid=A716148328&rfr_iscdi=true